CorMedix Q2 Revenue Jumps 157% to $101.9M, Raises Full-Year EBITDA Guidance
CRMD sits 22% above its 52-week low of $6.125.
Summary
CorMedix reported Q2 2026 revenue of $101.9 million, up 157% year-over-year, with net income of $26.0 million. The company raised full-year adjusted EBITDA guidance to $125-$140 million and announced a new DefenCath supply agreement with a large dialysis operator.
Key Events · Earnings and Guidance · CRMD
-
Q2 Revenue More Than Doubles
Consolidated revenue reached $101.9 million in Q2 2026, up from $39.7 million in Q2 2025, driven by $66.1 million in DefenCath sales and $35.8 million from the Melinta portfolio.
-
Full-Year EBITDA Guidance Raised
Adjusted EBITDA guidance for 2026 was raised to $125-$140 million, up from prior expectations, while revenue guidance was maintained at $325-$345 million.
-
New DefenCath Supply Agreement
Signed a multi-year commercial supply agreement with a Large Dialysis Operator, expanding coverage to all top 5 U.S. dialysis providers; the operator has begun ordering and will start a pilot in Q3 2026.
-
REZZAYO sNDA Submission Planned
In collaboration with Mundipharma, the company anticipates FDA submission of the sNDA for REZZAYO prophylaxis in Q3 2026, with potential agency action in H1 2027.
Analysis · CRMD · Life Sciences
A standout quarter for CorMedix, with revenue more than doubling year-over-year on the strength of DefenCath sales and the Melinta portfolio. Management's decision to raise full-year adjusted EBITDA guidance signals confidence in profitability, even as DefenCath reimbursement is expected to decline later this year. The new supply agreement with a large dialysis operator extends commercial reach to all top 5 U.S. dialysis providers, and the planned REZZAYO sNDA submission in Q3 2026 adds a near-term pipeline catalyst.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRMD was trading at $7.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557M. The 52-week trading range was $6.13 to $14.96. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.